Fibrosis mechanisms in systemic sclerosis and new potential therapies

Area of Science:

• Rheumatology
• Immunology
• Fibrosis Research

Background:

• Systemic sclerosis (SSc) is a rare autoimmune disease marked by immune cell activation, endothelial dysfunction, and progressive fibrosis.
• Pathological fibrosis in SSc results from extracellular matrix synthesis disorders, affecting skin and internal organs.
• Key molecular players include TGFβ, VEGF, Galectin-3, and the Wnt/β-catenin pathway.

Purpose of the Study:

• To review emerging therapeutic evidence for systemic sclerosis.
• To focus on innovative treatment strategies targeting key molecular pathways and cellular components.
• To provide insights into potential novel drug targets and therapeutic approaches for SSc.

Main Methods:

• Literature review of current and emerging therapeutic strategies for systemic sclerosis.
• Analysis of drugs targeting collagen, cytokines, and cell surface molecules.
• Examination of biologics, JAK inhibitors, IL-6 pathway modulators, monoclonal antibodies, and hypomethylating agents.

Main Results:

• Current treatments for SSc are diverse and tailored to disease subtype and progression.
• Monoclonal antibodies and hypomethylating agents show promise in inhibiting fibrosis.
• Emerging drugs target specific molecular pathways and cellular interactions involved in SSc pathogenesis.

Conclusions:

• Systemic sclerosis treatment requires a multi-faceted approach.
• Targeting collagen, cytokines, and cell surface molecules represents a promising avenue for innovative SSc therapies.
• Further research into novel therapeutic strategies is crucial for improving patient outcomes in SSc.